|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
US6322789B1
(en)
|
1991-08-26 |
2001-11-27 |
Epimmune, Inc. |
HLA-restricted hepatitis B virus CTL epitopes
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
DE614989T1
(de)
|
1993-02-17 |
1995-09-28 |
Morphosys Proteinoptimierung |
Verfahren für in vivo Selektion von Ligandenbindende Proteine.
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US20050003431A1
(en)
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
|
US6218363B1
(en)
|
1996-08-28 |
2001-04-17 |
Thomas Jefferson University |
MHC peptides and methods of use
|
|
DE69836209D1
(de)
|
1997-02-13 |
2006-11-30 |
Univ California |
Vorbeugung und behandlunhg des hepatozellulären krebses
|
|
US7098306B2
(en)
|
1997-02-13 |
2006-08-29 |
The Regents Of The University Of California |
Method and compositions for treating hepatocellular cancer
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
JP4480800B2
(ja)
|
1997-05-08 |
2010-06-16 |
オンコシリオン・インコーポレイテッド |
活性化ｔ細胞および抗原パルス標識した抗原提示細胞を生成する方法
|
|
US20030007978A1
(en)
|
1997-09-16 |
2003-01-09 |
Burrows Gregory G. |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6696304B1
(en)
|
1999-02-24 |
2004-02-24 |
Luminex Corporation |
Particulate solid phase immobilized protein quantitation
|
|
DE60044247D1
(de)
|
1999-04-30 |
2010-06-02 |
Inst Rech S Cliniques De Montr |
Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
|
|
US20020006664A1
(en)
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
EP1287363A2
(en)
|
2000-05-25 |
2003-03-05 |
Sunol Molecular Corporation |
Modulation of t-cell receptor interactions
|
|
US20020122820A1
(en)
|
2001-01-16 |
2002-09-05 |
Hildebrand William H. |
Soluble MHC artificial antigen presenting cells
|
|
US6800748B2
(en)
|
2001-01-25 |
2004-10-05 |
Large Scale Biology Corporation |
Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
|
|
ES2747357T3
(es)
|
2001-03-14 |
2020-03-10 |
Dako Denmark As |
Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
|
|
WO2002093129A2
(en)
|
2001-05-15 |
2002-11-21 |
University Of Medicine & Dentistry Of New Jersey |
Methods for analyzing interactions between proteins in live and intact cells
|
|
US20040161817A1
(en)
|
2001-06-04 |
2004-08-19 |
Corixa Corporation |
Compositions and methods for high-level, large-scale production of recombinant proteins
|
|
US20030017134A1
(en)
|
2001-06-19 |
2003-01-23 |
Technion Research And Development Foundation Ltd. |
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
|
|
EP1497426A2
(en)
|
2001-06-22 |
2005-01-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
AU2002322211A1
(en)
|
2001-07-12 |
2003-01-29 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
|
AU2002363354A1
(en)
|
2001-07-27 |
2003-05-19 |
Human Genome Sciences, Inc. |
Heteromultimeric tnf ligand family members
|
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
WO2003077834A2
(en)
|
2002-03-15 |
2003-09-25 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
CA2498319A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
EP1599502A1
(en)
|
2003-02-27 |
2005-11-30 |
TheraVision GmbH |
A molecule which binds cd80 and cd86
|
|
AU2003901876A0
(en)
|
2003-04-17 |
2003-05-08 |
The Macfarlane Burnet Institute For Medical Research And Public Health |
Viral vector
|
|
US20050042641A1
(en)
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
|
US7696306B2
(en)
|
2003-07-11 |
2010-04-13 |
Board of Agents of the University of Nebraska |
Compositions and methods for preventing or treating cancer
|
|
CA2537759C
(en)
|
2003-09-05 |
2015-03-24 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
US7470513B2
(en)
|
2003-11-10 |
2008-12-30 |
Academia Sinica |
Risk assessment for adverse drug reactions
|
|
EP1723251A4
(en)
|
2004-03-05 |
2008-04-23 |
Novartis Vaccines & Diagnostic |
IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
|
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
|
AU2005247950B2
(en)
|
2004-05-27 |
2012-02-02 |
Receptor Logic, Inc. |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
|
JP2009515521A
(ja)
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス， インコーポレイテッド |
レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
|
|
US7943133B2
(en)
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
DK2402754T4
(da)
|
2006-03-06 |
2023-08-28 |
Amunix Operating Inc |
Ustrukturerede rekombinante polymerer og anvendelser deraf
|
|
US8518697B2
(en)
|
2006-04-04 |
2013-08-27 |
Washington University |
Single chain trimers and uses therefor
|
|
ZA200810677B
(en)
|
2006-05-19 |
2010-03-31 |
Teva Pharma |
Fusion proteins, uses thereof and processes for producing same
|
|
EP1889851A1
(en)
|
2006-08-18 |
2008-02-20 |
Charite Universitätsmedizin-Berlin |
PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
CA2886621A1
(en)
|
2006-12-28 |
2008-07-10 |
International Institute Of Cancer Immunology, Inc. |
Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
|
|
AU2008216669B2
(en)
|
2007-02-15 |
2013-12-12 |
Mannkind Corporation |
A method for enhancing T cell response
|
|
WO2008113970A2
(en)
|
2007-03-16 |
2008-09-25 |
Ucl Business Plc |
Peptides
|
|
EP2155782A2
(en)
|
2007-03-26 |
2010-02-24 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
|
US8926961B2
(en)
|
2007-10-03 |
2015-01-06 |
Board Of Trustees Of The University Of Arkansas |
HPV E6 protein T cell epitopes and uses thereof
|
|
CN101418309B
(zh)
|
2007-10-23 |
2011-05-04 |
中国农业科学院上海兽医研究所 |
柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
TW201008574A
(en)
|
2008-08-19 |
2010-03-01 |
Oncotherapy Science Inc |
INHBB epitope peptides and vaccines containing the same
|
|
US20110318380A1
(en)
|
2008-10-01 |
2011-12-29 |
Dako Denmark A/S |
MHC Multimers in Cancer Vaccines and Immune Monitoring
|
|
EP2184070A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G proteins and pharmaceutical uses thereof
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US20110274650A1
(en)
|
2009-01-21 |
2011-11-10 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
CA2764860C
(en)
|
2009-06-25 |
2018-04-24 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
BR112013000985A2
(pt)
|
2010-07-15 |
2017-09-05 |
Technion Res & Dev Foundation |
Entidades isoladas de alta afinidade com especificidade semelhante à do receptor de célula t em relação a complexos nativos de mhc classe ii e peptídeos autoantigênicos de descarboxilase do ácido glutâmico (gad)
|
|
EP2619229B1
(en)
|
2010-09-21 |
2016-04-06 |
Altor BioScience Corporation |
Multimeric il-15 soluble fusion molecules and methods of making and using same
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
HUE029139T2
(hu)
*
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
PE20141212A1
(es)
|
2011-06-22 |
2014-09-19 |
Hoffmann La Roche |
Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
|
|
PT2726101T
(pt)
|
2011-06-30 |
2018-11-21 |
Genzyme Corp |
Inibidores da ativação de células t
|
|
WO2013030620A2
(de)
|
2011-08-30 |
2013-03-07 |
Jacobs University Bremen Ggmbh |
Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
CA2861206C
(en)
|
2012-01-13 |
2021-07-06 |
Richard J. O'reilly |
Immunogenic wt-1 peptides and methods of use thereof
|
|
US20150071987A1
(en)
|
2012-02-03 |
2015-03-12 |
Emory University |
Immunostimulatory compositions, particles, and uses related thereto
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
WO2014083004A1
(en)
|
2012-11-30 |
2014-06-05 |
Roche Glycart Ag |
Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
|
|
US10048271B2
(en)
|
2012-12-11 |
2018-08-14 |
Albert Einstein College Of Medicine, Inc. |
Methods for high throughput receptor:ligand identification
|
|
WO2014096015A1
(en)
|
2012-12-21 |
2014-06-26 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
|
CN110078813B
(zh)
|
2013-01-15 |
2023-03-28 |
纪念斯隆凯特林癌症中心 |
免疫原性wt-1肽和其使用方法
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
US20140242077A1
(en)
|
2013-01-23 |
2014-08-28 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
HK1220376A1
(zh)
|
2013-03-15 |
2017-05-05 |
Angelica Therapeutics, Inc. |
修饰的毒素
|
|
EP3936521B1
(en)
|
2013-03-15 |
2026-02-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2982681B8
(en)
|
2013-03-29 |
2018-11-07 |
Sumitomo Dainippon Pharma Co., Ltd. |
Wt1-antigen peptide conjugate vaccine
|
|
CA2912514A1
(en)
|
2013-05-13 |
2014-11-20 |
International Institute Of Cancer Immunology, Inc. |
Method for predicting clinical effect of immunotherapy
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
AU2014291961B2
(en)
|
2013-07-19 |
2018-09-27 |
Centre Hospitalier Regional Universitaire De Montpellier |
Targeted modified TNF family members
|
|
EP4043493A1
(en)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
SG11201605632SA
(en)
|
2014-01-21 |
2016-08-30 |
Einstein Coll Med |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
WO2015130766A1
(en)
|
2014-02-25 |
2015-09-03 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
US10253075B2
(en)
|
2014-02-26 |
2019-04-09 |
tella, Inc. |
WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
|
|
US10150802B2
(en)
|
2014-04-24 |
2018-12-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
PT3480213T
(pt)
|
2014-06-18 |
2020-02-04 |
Albert Einstein College Medicine |
Polipéptidos syntac e utilizações dos mesmos
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
WO2016014428A2
(en)
|
2014-07-21 |
2016-01-28 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2016025642A1
(en)
*
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
US11111284B2
(en)
|
2014-08-21 |
2021-09-07 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
|
|
CA2951604A1
(en)
|
2014-08-29 |
2016-03-03 |
Pablo Umana |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
CN107531805A
(zh)
|
2015-03-05 |
2018-01-02 |
弗雷德哈钦森癌症研究中心 |
免疫调节融合蛋白及其用途
|
|
EP3286222A4
(en)
|
2015-03-23 |
2018-08-08 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
RS61943B1
(sr)
|
2015-04-17 |
2021-07-30 |
Alpine Immune Sciences Inc |
Imunomodulatorni proteini sa prilagodljivim afinitetima
|
|
SG10201913957PA
(en)
|
2015-05-06 |
2020-03-30 |
Uti Lp |
Nanoparticle compositions for sustained therapy
|
|
CA2991976A1
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
US11046745B2
(en)
|
2015-07-14 |
2021-06-29 |
BioNTech SE |
Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017023779A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
CN106565836B
(zh)
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
SMT202200370T1
(it)
|
2015-11-20 |
2022-11-18 |
Memorial Sloan Kettering Cancer Center |
Composizione per il trattamento del cancro
|
|
JP6904959B2
(ja)
|
2016-01-04 |
2021-07-21 |
クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド |
結合エピトープを含有する融合タンパク質を封入する粒子
|
|
CN108602857A
(zh)
|
2016-01-27 |
2018-09-28 |
瑞士杰特贝林生物制品重组设备股份公司 |
重组IgG Fc多聚体
|
|
CA3014458A1
(en)
*
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
AU2017225787B2
(en)
|
2016-03-03 |
2021-09-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CN115073581A
(zh)
|
2016-05-04 |
2022-09-20 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
AU2017266905B2
(en)
*
|
2016-05-18 |
2022-12-15 |
Albert Einstein College Of Medicine, Inc. |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
US11505591B2
(en)
|
2016-05-18 |
2022-11-22 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20260011774A
(ko)
|
2016-11-09 |
2026-01-23 |
유티아이 리미티드 파트너쉽 |
재조합 pMHC II형 분자
|
|
KR102760578B1
(ko)
|
2016-12-22 |
2025-02-03 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
MX2019010812A
(es)
|
2017-03-17 |
2019-12-11 |
Hutchinson Fred Cancer Res |
Proteinas de fusion inmunomoduladoras y sus usos.
|
|
EP3446702A1
(en)
|
2017-08-23 |
2019-02-27 |
Medizinische Hochschule Hannover |
Synthetic vaccine
|
|
TW201925235A
(zh)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
TW201920249A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
具有結合位點之t細胞調節多聚體多肽及其使用方法
|
|
EA202090471A1
(ru)
|
2017-09-07 |
2020-06-10 |
Кью Биофарма, Инк. |
Модулирующие т-клетки мультимерные полипептиды и способы их применения
|
|
EP3692063A1
(en)
|
2017-10-03 |
2020-08-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
EP3755711A4
(en)
|
2018-02-20 |
2021-11-24 |
Technion Research & Development Foundation Limited |
IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
AU2019401183A1
(en)
|
2018-12-19 |
2021-08-12 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2020132135A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
EP3935080A4
(en)
|
2019-03-06 |
2023-04-05 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
AU2020282736B2
(en)
|
2019-05-29 |
2025-10-30 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
CA3142738A1
(en)
|
2019-06-05 |
2020-12-10 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
WO2021055594A1
(en)
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
AU2020370292A1
(en)
|
2019-10-23 |
2022-03-03 |
Cue Biopharma, Inc. |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
EP4048402A4
(en)
|
2019-10-23 |
2023-11-22 |
Cue Biopharma, Inc. |
MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF
|
|
IL293330A
(en)
|
2019-12-02 |
2022-07-01 |
Regeneron Pharma |
mhc ii peptide protein structures and uses thereof
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
WO2021172596A1
(ja)
|
2020-02-28 |
2021-09-02 |
国立大学法人金沢大学 |
免疫制御法、免疫制御用核酸組成物およびその用途
|
|
GB202005617D0
(en)
|
2020-04-17 |
2020-06-03 |
Adaptimmune Ltd |
Improved t cell manufacturing process
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
CN113823723A
(zh)
|
2020-06-18 |
2021-12-21 |
光宝光电(常州)有限公司 |
发光二极管封装结构
|
|
KR20230052881A
(ko)
|
2020-07-14 |
2023-04-20 |
큐 바이오파마, 인크. |
접합 부위를 갖는 t-세포 조절 폴리펩티드 및 이의 사용 방법
|
|
US12024559B2
(en)
|
2020-10-23 |
2024-07-02 |
Asher Biotherapeutics, Inc. |
Fusions with CD8 antigen binding molecules for modulating immune cell function
|
|
AU2021397271A1
(en)
|
2020-12-09 |
2023-07-06 |
Asher Biotherapeutics, Inc. |
Targeted cytokine construct for engineered cell therapy
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|